Diffusion MRI shown to give early signs of cancer's response to treatment

December 18, 2000

May soon help save patients and physicians precious time

ANN ARBOR, Mich. - Cancer patients who now endure months of treatment - and then weeks of anxious waiting to see if it worked - may soon get word of their tumors' response within days of starting therapy, thanks to a new use for a widely available MRI technique.

In the first study of its kind, researchers from the University of Michigan Comprehensive Cancer Center are reporting success in analyzing diffusion MRI images to distinguish between dead and living brain tumor cells in both animals and humans. They report that the imaging technique, which tracks the movement of water through and between cells, allowed them to assess the effect of therapy on the cancer without relying on measurable changes in tumor size.

Published in the Dec. 20 issue of the Journal of the National Cancer Institute, the early finding has the potential to dramatically change the way physicians plan and track the effectiveness of the cancer therapies they prescribe. It could spare patients the physical side effects of weeks of unsuccessful treatment, and the psychological effects of then waiting a month or more for an MRI scan to show if they're responding. And, it could aid in testing new anti-cancer agents.

"One of the biggest problems in dealing with many solid cancers is measuring their response to treatment in a timely way," says corresponding author Brian Ross, Ph.D. "Diffusion MRI seems to provide a way to gauge that response faster, and could individualize the clinical management of each patient." Ross is an associate professor of radiology and biological chemistry and co-director - with associate professor of radiation oncology and co-author Alnawaz Rehemtullah, Ph.D. - of the U-M Health System's Center for Molecular Imaging.

Already widely in use to diagnose strokes, diffusion MRI can be done using nearly any closed MRI scanner and adds just a few minutes to a regular scan, says lead author and UMHS physicist Thomas Chenevert, Ph.D. The new study looks at brain tumors, but the U-M team has already shown the technique is useful in other solid cancers in animals and humans.

The researchers stress that the technique has not been, and is not yet ready to be, used in any cancer patient's actual treatment planning. To learn more about its worth, they're working with colleagues elsewhere on further studies of the approach. They're also continuing to test it at the U-M, and are planning a multi-center clinical trial for late 2001.

MRI, which stands for magnetic resonance imaging, makes images of the body's inner structure using a strong magnetic field that aligns the body's water molecules. Since water makes up the bulk of every kind of tissue, the images reflect the differences among various tissues' water content and density. So, for example, bone and muscle show up in different shades of gray.

MRI is now one of the most common forms of medical imaging technology, used to help study patients' anatomy and diagnose disease. It's also routinely used before and after cancer treatment, to aid physicians in measuring the size of tumors and assessing a patient's progress.

But even though cancer treatments like chemotherapy or radiation kill tumor cells immediately, it can often be weeks before the body absorbs enough of the dead cells to produce a change in tumor size that's visible on an MRI scan. Meanwhile, the rest of the tumor may keep growing. If the tumor isn't responding at all, the delay wastes time that could be spent on other treatment.

The U-M team's approach seeks a more rapid answer using the extra information provided by diffusion MRI, which takes the concept of tracking water molecules a step further. Diffusion MRI can assess how easily water is moving across microscopic distances - a continuous process called diffusion. Healthy cells have unbroken outer membranes that slow water's movement, but the membranes around dying or dead cells break down, allowing water to diffuse freely.

MRI machines can be programmed to be sensitive to the ease of this water movement in different areas of tissue. The use of diffusion MRI in stroke, for example, gives doctors a rapid view of brain regions where blood flow is cut off by a blood hemorrhage or clot.

The U-M post-scan processing technique takes the information from a diffusion MRI scan and analyzes it to give a measure of cells' membrane integrity throughout and near a tumor. It uses a measurement called the apparent diffusion coefficient, or ADC.

The new study compared scans taken before and after the animals and humans were treated for their brain tumors. Brain tumors, some of the hardest cancers to treat, cause 26 percent of childhood cancer deaths and 2 percent of adult cancer deaths.

The animal study looked at 16 rats with induced tumors treated with a range of doses of the chemotherapy drug BCNU. They had MRIs before treatment and every other day following treatment. Diffusion increased in the first week, even as tumor size actually grew. On the eighth day, ADC peaked. Soon after, the tumors began to regress, though they later grew back from surviving cells. The magnitude and length of the diffusion response increased with dose.

The two early human patients - a 13-year-old girl and a 37-year-old man - agreed to let the researchers analyze the conventional and diffusion MRI scans they received before, during and after treatment. Both had surgery and chemotherapy preceded or followed by radiation therapy.

The girl's tumor stopped growing but did not shrink appreciably following initial radiation treatment. It began growing again almost a year later. Early on in treatment, diffusion increased slightly during several months of therapy. Around the time when the tumor began growing again, the ADC went down dramatically, corresponding to an increase in the number of intact cell membranes. The man's tumor responded better, and at six weeks after treatment began the ADC peaked, going up by 86 percent. Over time, his tumor shrank to about half its original size.
The research was sponsored in part by the Charles A. Dana Foundation, the National Cancer Institute and the U-M Clinical Research Partnership Fund.

University of Michigan Health System

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.